Targeting Colorectal Cancer Stem Cells Through Inhibition of the Fibroblast Growth Factor Receptor 4 Pathway with a Novel Antibody
This study successfully identified several CSC-selective membrane antigens that can become therapeutic targets in CRC. Among them, we focused on FGFR4 as a promising target and developed the anti-FGFR4 3B6 monoclonal antibody which offers potential for both diagnostic and therapeutic applications.
Authors
- Armin Lahm (ORCID: https://orcid.org/0000-0002-2859-4379)
- Chantal Paolini
- Mauro Biffoni (ORCID: https://orcid.org/0000-0002-1304-9060)
- Giorgia Castellani
- Gessica Filocamo
- Mariachiara Buccarelli (ORCID: https://orcid.org/0000-0003-1157-4694)
- Michele Signore (ORCID: https://orcid.org/0000-0002-0262-842X)
- Alessandra Boe (ORCID: https://orcid.org/0000-0002-8888-7501)
- Mirko Brunetti
- Romina Alfonsi (ORCID: https://orcid.org/0000-0001-5100-5491)
- Ruggero De Maria
- Lucia Ricci-Vitiani
- Christian Steinkühler
- Gabriele De Luca
Institutions
- Università Cattolica del Sacro Cuore (IT)
- Istituto Superiore di Sanità (IT)
- Agostino Gemelli University Polyclinic (IT)
- Rome International School (IT)
- Institute of Bioinformatics (IN)
- IRBM Science Park (IT)
- Italfarmaco (Italy) (IT)
- Istituti di Ricovero e Cura a Carattere Scientifico (IT)
Publication Details
- Journal
- Cancers
- Published
- 2026-01-28
- DOI
- https://doi.org/10.3390/cancers18030418
- Primary Topic
- Fibroblast Growth Factor Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00